Vermillion Posts $344,000 in Q2 Revenues, Including First Sales of OVA1 Test

Vermillion said that 1,247 OVA1 tests were performed during the quarter, and it recognized revenue for 342 of them. The company expects to sell between 8,000 and 10,000 OVA1 tests total in 2010, and believes there is an opportunity to eventually sell more than 1 million tests per year.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.